MEI Pharma http://investor.meipharma.com/ MEI Pharma Reports First Quarter Fiscal Year 2018 Results http://investor.meipharma.com/2017-11-08-MEI-Pharma-Reports-First-Quarter-Fiscal-Year-2018-Results Quarter highlighted by dosing of first patient in pivotal Phase 3 study of pracinostat and exclusive license agreement for voruciclib Wed, 08 Nov 2017 06:00:00 -0800 http://investor.meipharma.com/2017-11-08-MEI-Pharma-Reports-First-Quarter-Fiscal-Year-2018-Results MEI Pharma to Present at Stifel 2017 Healthcare Conference http://investor.meipharma.com/2017-11-07-MEI-Pharma-to-Present-at-Stifel-2017-Healthcare-Conference Live Webcast from New York on November 15th Tue, 07 Nov 2017 06:00:00 -0800 http://investor.meipharma.com/2017-11-07-MEI-Pharma-to-Present-at-Stifel-2017-Healthcare-Conference MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference http://investor.meipharma.com/2017-09-19-MEI-Pharma-to-Present-at-Cantor-Fitzgerald-Global-Healthcare-Conference Live Webcast from New York on September 26th Tue, 19 Sep 2017 06:00:00 -0700 http://investor.meipharma.com/2017-09-19-MEI-Pharma-to-Present-at-Cantor-Fitzgerald-Global-Healthcare-Conference MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor http://investor.meipharma.com/2017-09-05-MEI-Pharma-Announces-Exclusive-License-Agreement-with-Presage-Biosciences-for-Voruciclib-An-Oral-Selective-CDK-Inhibitor Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value Tue, 05 Sep 2017 13:05:00 -0700 http://investor.meipharma.com/2017-09-05-MEI-Pharma-Announces-Exclusive-License-Agreement-with-Presage-Biosciences-for-Voruciclib-An-Oral-Selective-CDK-Inhibitor MEI Pharma Reports Fiscal Year 2017 Results http://investor.meipharma.com/2017-09-05-MEI-Pharma-Reports-Fiscal-Year-2017-Results Company Begins New Fiscal Year with $53.6 Million in Cash Tue, 05 Sep 2017 05:30:00 -0700 http://investor.meipharma.com/2017-09-05-MEI-Pharma-Reports-Fiscal-Year-2017-Results